SLC1A2 and relapsing-remitting multiple sclerosis: Screening of plasma samples for the presence of EV-EAAT2 showed a statistically significant increase in EV-EAAT2 levels in relapsing RRMS patients compared to remitting RRMS patients, SPMS patients and healthy controls, regardless of DMT exposure.